TABLE 1 

Subject demographics and serologic findings from DENV immune subjects studiedb

Type of
infection
Infecting
virus
Infecting
serotype(s)
Subject
no.a
Location
acquired
Yr
infected
Time
since
infection
Reciprocal serum antibody
50% neutralization titer, to
indicated DENV serotype
No. of
DENV
FL-specific
hybridomas
obtained
D1D2D3D4
PrimaryLive attenuated
vaccine
149U.S. NIH
vaccine trial
20087 mo37NDNDND1
Natural
wild-type
field strain
1106India20072 yr90<<<3
10Thailand20027 yr254<<<1
219Thailand19978 yr95>201051
3118Nicaragua20091 yr6032980761
3Thailand20014 yr3087338<2
SecondaryNatural
wild-type
field strains
Multiple1089Nicaragua20091 yr107220200701
3387Nicaragua20091 yr1,000400340902
115Sri Lanka1974–199712 yr901343301651
9India-Sri Lanka20005 yr>>2903931
184Mexico20064 yr2822091667616
  • a Subject numbers were assigned in the original clinical studies, as outlined in Materials and Methods.

  • b Symbols: >, titer greater than 1:1,280; <, titer less than 1:20; ND, not determined.